Fatty liver protection trial by Telmisartan or Losartan Study

Fatty liver protection trial by Telmisartan or Losartan Study - FANTASY study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000540

Enrollment

130

Registered

2006-12-10

Start date

2006-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with non alcoholic fatty liver disease

Interventions

Telmisartan Losartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertension (SBP>140 or DBP>90) Non alcoholic fatty liver disease

Exclusion criteria

Exclusion criteria: Drug allergy for the agents. Severe liver dysfunction. Insulin treatment for diabetes mellistus. Malignancy. Recent major macrovascular disease. Severe hypertension.

Design outcomes

Primary

Measure	Time frame
Improvement of liver function (AST, ALT)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026